Impact of Beta Blockers on TAVI (BETA-TAVI) - Trial NCT05721170
Access comprehensive clinical trial information for NCT05721170 through Pure Global AI's free database. This Phase 4 trial is sponsored by National and Kapodistrian University of Athens and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National and Kapodistrian University of Athens
Timeline & Enrollment
Phase 4
Mar 01, 2023
Jan 31, 2025
Primary Outcome
Permanent pacemaker implantation
Summary
This is a prospective, multicentre, investigator-initiated, randomized clinical trial
 clinical trial investigating the impact of beta-blockers administration among patients
 undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be
 assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at
 least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent
 pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include
 death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05721170
Non-Device Trial